Loading
Obesity / Weight Loss / Antibiotic treatment · Interventional Study
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a recruiting interventional trial (NCT06681246) designed to evaluate whether oral antibiotic treatment after weight loss can prevent weight regain by modulating gut microbiota composition. The study is in recruitment phase with no results yet posted in this registry record. A definitive conclusion on efficacy cannot be drawn until the trial is completed and results are published.
Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Obesity, Weight Loss; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: Antibiotic treatment. Compared with: Placebo — Placebo Comparator. n = 200. 1 site: Israel.
This is a recruiting interventional trial (NCT06681246) designed to evaluate whether oral antibiotic treatment after weight loss can prevent weight regain by modulating gut microbiota composition. The study is in recruitment phase with no results yet posted in this registry record. A definitive conclusion on efficacy cannot be drawn until the trial is completed and results are published.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a recruiting clinical trial registration with no results posted; it describes a planned interventional study examining microbiome modulation and antibiotic treatment to prevent weight regain in obesity.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06681246). This is a study registration, not published results. Lead sponsor: Weizmann Institute of Science. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Obesity, Weight Loss. Interventions: OTHER: Antibiotic treatment; OTHER: Placebo. Primary outcome measures: microbiome composition , 1 year; weight , 1 year. Brief summary: This past century witnessed a significant increase in the prevalence of obesity. Successful weight loss maintenance is defined as losing at least 10% of the initial body weight and maintaining it for at least one year. However, keeping a low body weight is rarely maintained, as 80% of people who lost 10% of their body weight will return to their initial weight within a year. Although there is no agreement as to what contributes to the recurrent weight regain phenomenon (also known as 'weight cycling' or 'yo-yo diet'), it is strongly associated with the risk of developing metabolic risk factors and their complications, including heart disease and all-cause mortality. Altering the gut microbiota is one method to treat disease states associated with gut bacteria. Antibiotics consumption is known to influence host glycemic response through changes induced in microbiome composition and function. Therefore, it may be a possible pathway to jumpstart changes in the gut microbiota. This study will determine whether microbiome modulation might be a possible future target against recurrent obesity in humans and whether orally administered antibiotic treatment post-weight loss might be an effective intervention to prevent weight regain.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.